Phase I/II Trial of AGS-003

Article

Argos Therapeutics has begun a phase I/II clinical trial to test the activity and safety of AGS-003, a personalized immunotherapy for advanced kidney cancer. AGS-003 is a second-generation dendritic-cell-based therapy with optimized immune response characteristics designed to stimulate the immune system to target and destroy cancer cells.

DURHAM, North Carolina—Argos Therapeutics has begun a phase I/II clinical trial to test the activity and safety of AGS-003, a personalized immunotherapy for advanced kidney cancer. AGS-003 is a second-generation dendritic-cell-based therapy with optimized immune response characteristics designed to stimulate the immune system to target and destroy cancer cells.

Recent Videos
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Barry J. Byrne, MD, PhD, the chief medical advisor of Muscular Dystrophy Association (MDA) and a physician-scientist at the University of Florida
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Chun-Yu Chen, PhD, a research scientist at Seattle Children’s Research Institute
William Chou, MD, on Targeting Progranulin With Gene Therapy for Frontotemporal Dementia
Alexandra Collin de l’Hortet, PhD, the head of therapeutics at Epic Bio
David Dimmock, MBBS, on Accelerating Therapy Discovery and Approval With AI David Dimmock, MBBS, on Accelerating Therapy Discovery and Approval With AI
Joshua M. Hare, MD, on Working to Address Unmet Needs in Alzheimer Disease With Lomecel-B Cell Therapy
John Finn, PhD, the chief scientific officer of Tome Biosciences
Related Content
Rocket Pharmaceuticals Maxes Out Recruitment in Pivotal Trial for Danon Disease Gene Therapy RP-A501

Rocket Pharmaceuticals Maxes Out Recruitment in Pivotal Trial for Danon Disease Gene Therapy RP-A501

Noah Stansfield
September 19th 2024
Article

The single-arm trial enrolled 12 male patients in total across the United States and European Union.

Around the Helix: Cell and Gene Therapy Company Updates – September 18, 2024

Around the Helix: Cell and Gene Therapy Company Updates – September 18, 2024

Noah Stansfield
September 18th 2024
Article

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Jeffrey Chamberlain, PhD, Professor, Neurology and Medical Genetics, and Adjunct Professor, Biochemistry, and McCaw Endowed Chair of Muscular Dystrophy at University of Washington

Ongoing Research Seeks to Address Challenges With Muscular Dystrophy Gene Therapy

Jeffrey S. Chamberlain, PhD;Noah Stansfield
September 18th 2024
Article

Jeffrey Chamberlain, PhD, McCaw Endowed Chair of Muscular Dystrophy at University of Washington, highlighted studies presented at MDA's 2024 conference.

Vironexis Biotherapeutics’ AAV Vector-Based Immunotherapy VNX-101 Cleared for US Trial in Acute Lymphoblastic Leukemia

Vironexis Biotherapeutics’ AAV Vector-Based Immunotherapy VNX-101 Cleared for US Trial in Acute Lymphoblastic Leukemia

Noah Stansfield
September 17th 2024
Article

VNX-101 is intended to transduce cells of the liver, causing them to express a transgene coding for a bispecific T-cell engager.

Data Roundup: June 2024 Features Updates from ASCO and in Diabetes, Rare Disease, and more.

Data Roundup: August 2024 Features Updates in CAR-T, mRNA Therapy, and Gamma Delta T-cell Therapy for Various Cancers

CGTLive Staff
September 17th 2024
Article

Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive™ team.

BridgeBio Pharma Drops Development of Congenital Adrenal Hyperplasia Gene Therapy BBP-631

BridgeBio Pharma Drops Development of Congenital Adrenal Hyperplasia Gene Therapy BBP-631

Noah Stansfield
September 16th 2024
Article

The company made the decision to axe the program in light of newly reported topline results from the clinical study.

© 2024 MJH Life Sciences

All rights reserved.